SG11201806595UA - Using cell-free dna fragment size to determine copy number variations - Google Patents

Using cell-free dna fragment size to determine copy number variations

Info

Publication number
SG11201806595UA
SG11201806595UA SG11201806595UA SG11201806595UA SG11201806595UA SG 11201806595U A SG11201806595U A SG 11201806595UA SG 11201806595U A SG11201806595U A SG 11201806595UA SG 11201806595U A SG11201806595U A SG 11201806595UA SG 11201806595U A SG11201806595U A SG 11201806595UA
Authority
SG
Singapore
Prior art keywords
california
copy number
international
fragments
illinois
Prior art date
Application number
SG11201806595UA
Inventor
Sven Duenwald
David A Comstock
Catalin Barbacioru
Darya I Chudova
Richard P Rava
Keith W Jones
Gengxin Chen
Dimitri Skvortsov
Original Assignee
Verinata Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verinata Health Inc filed Critical Verinata Health Inc
Publication of SG11201806595UA publication Critical patent/SG11201806595UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869Methods for sequencing
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06FELECTRIC DIGITAL DATA PROCESSING
    • G06F18/00Pattern recognition
    • G06F18/20Analysing
    • G06F18/23Clustering techniques
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06FELECTRIC DIGITAL DATA PROCESSING
    • G06F18/00Pattern recognition
    • G06F18/20Analysing
    • G06F18/24Classification techniques
    • G06F18/243Classification techniques relating to the number of classes
    • G06F18/24323Tree-organised classifiers
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/10Ploidy or copy number detection
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10Sequence alignment; Homology search
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16ZINFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00Subject matter not provided for in other main groups of this subclass
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/16Assays for determining copy number or wherein the copy number is of special importance
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/165Mathematical modelling, e.g. logarithm, ratio
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/154Methylation markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Data Mining & Analysis (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Databases & Information Systems (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Primary Health Care (AREA)
  • Evolutionary Computation (AREA)
  • Artificial Intelligence (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Software Systems (AREA)
  • Signal Processing (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization IIIMI41101110101011111 HO 11111011101110011001111101110111110 ill OEN International Bureau ... .1 j (10) International Publication Number (43) International Publication Date ..... ....r;,' WO 2017/136059 Al 10 August 2017(10.08.2017) WIPO I PCT (51) International Patent Classification: JONES, Keith W.; 499 Illinois Street, #210, San Fran- C12Q 1/68 (2006.01) G06F 19/22 (2011.01) cisco, California 94158 (US). CHEN, Gengxin; 499 G06F 19/24 (2011.01) G06F 19/00 (2011.01) Illinois Street, #210, San Francisco, California 94158 G06F 19/18 (2011.01) (US). SKVORTSOV, Dimitri; 499 Illinois Street, #210, San Francisco, California 94158 (US). (21) International Application Number: PCT/US2016/067886 (74) Agents: ZHOU, Feng et al.; WEAVER AUSTIN VIL- LENEUVE & SAMPSON LLP, P. 0. Box 70250, Oak- (22) International Filing Date: land, California 94612-0250 (US). 20 December 2016 (20.12.2016) (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (30) Priority Data: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 62/290,891 3 February 2016 (03.02.2016) US HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, 15/382,508 16 December 2016 (16.12.2016) US KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (71) Applicant: VERINATA HEALTH, INC. [US/US]; 5200 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, Illumina Way, San Diego, California 92122 (US). NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (72) Inventors: DUENWALD, Sven; 499 Illinois Street, #210, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, San Francisco, California 94158 (US). COMSTOCK, ZA, ZM, ZW. _ David A.; 499 Illinois Street, #210, San Francisco, Califor- - nia 94158 (US). BARBACIORU, Catalin; 499 Illinois (84) Designated States (unless otherwise indicated, for every _ Street, #210, San Francisco, California 94158 (US). kind of regional protection available): ARIPO (BW, GH, CHUDOVA, Darya I.,; 5931 Taormino Avenue, San Jose, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, California 95123 (US). RAVA, Richard P.; 711 Edge- TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, wood Road, Redwood City, California 94062 (US). TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, = [Continued on next page] (54) Title: USING CELL-FREE DNA FRAGMENT SIZE TO DETERMINE COPY NUMBER VARIATIONS (57) : Disclosed are methods for determining copy number vari- ms 702 I . equencin data = _ 713A 1 7 7139 coverage coverage l short fragm al ents fragments , 713C ation (CNV) known or suspected to be associated with a variety of medical Relative R fre uenc conditions. In some embodiments, methods are provided for determining y of q short copy number variation of fetuses using maternal samples comprising mater- fragments nal and fetal cell free DNA. In some embodiments, methods are provided = — Convert & de multiplex (if I 1 i 71 for determining CNVs known or suspected to be associated with a variety of appficabie) Normalize binned site to total NES value disclosed herein provide methods _ . 1 1 medical conditions. Some embodiments = Alignment • 7 8 Remove global wave, flowcell/batch specific to improve the sensitivity and/or specificity of sequence data analysis by de- riving a fragment size parameter. In some implementations, information 3 71 I i 718 . Tag flitering 8 Binning Correct for GC level from fragments different of sizes are used to evaluate copy number vari- In some implementations, t from ations. one or more -statistics obtained coy- _ ! 7 9 information the interest is used to Compute count. Principle Component Analysis erage of sequence of evaluate copy num- ber In implementations, fetal fraction variations. some one or more estim- 722 = ates are more t-statistics to determine copy number combined with one or Single sample filter 1 variations. _ 72 nEnrichment d tar- etover reference Enrichment of target over reference Enrichment of target ave r reference 729 73r 7 Il One or more Fetal Fractions I statistic t statistic t statistic tz. kin Pass 1: coverage-ell fragments Ploidy Likelihood Pass 2: M coverage - short fragments Pass 3: — -- Figure 2E Il fiaquency of short fra \ .. IN Il © N O WO 2017/136059 Al MIDEDIM01101 DIVIIMMEMIIIM100III11111111111111110111111111111 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, before the expiration of the time limit for amending the LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SI, SK, SM, TR), OAPI GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (BF, BJ, CF, CG, CI, RS, CM, SE, GA, claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) Published: — with international search report (Art. 21(3))
SG11201806595UA 2016-02-03 2016-12-20 Using cell-free dna fragment size to determine copy number variations SG11201806595UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662290891P 2016-02-03 2016-02-03
US15/382,508 US10095831B2 (en) 2016-02-03 2016-12-16 Using cell-free DNA fragment size to determine copy number variations
PCT/US2016/067886 WO2017136059A1 (en) 2016-02-03 2016-12-20 Using cell-free dna fragment size to determine copy number variations

Publications (1)

Publication Number Publication Date
SG11201806595UA true SG11201806595UA (en) 2018-09-27

Family

ID=57583028

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806595UA SG11201806595UA (en) 2016-02-03 2016-12-20 Using cell-free dna fragment size to determine copy number variations

Country Status (20)

Country Link
US (3) US10095831B2 (en)
EP (2) EP3202915B1 (en)
KR (2) KR102184868B1 (en)
CN (2) CN113096726B (en)
AR (1) AR107192A1 (en)
AU (2) AU2016391100B2 (en)
BR (1) BR112018015913B1 (en)
CA (1) CA3013572C (en)
CY (1) CY1121741T1 (en)
DK (1) DK3202915T3 (en)
EA (2) EA202090277A3 (en)
IL (2) IL260938B (en)
MA (2) MA44822A (en)
NZ (1) NZ745637A (en)
SA (1) SA518392138B1 (en)
SG (1) SG11201806595UA (en)
TW (2) TWI708848B (en)
UA (1) UA126898C2 (en)
WO (1) WO2017136059A1 (en)
ZA (1) ZA201805753B (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9932576B2 (en) 2012-12-10 2018-04-03 Resolution Bioscience, Inc. Methods for targeted genomic analysis
KR102373647B1 (en) 2013-10-21 2022-03-11 베리나타 헬스, 인코포레이티드 Method for improving the sensitivity of detection in determining copy number variations
BR112016027848A2 (en) 2014-05-30 2017-08-22 Verinata Health Inc METHOD FOR EVALUATION OF THE NUMBER OF COPIES OF A SEQUENCE OF INTEREST, NON-TRANSITORY MACHINE- READABLE MEDIUM, AND, SYSTEM FOR EVALUATION OF THE NUMBER OF COPIES OF A SEQUENCE OF INTEREST
EP3502273B1 (en) 2014-12-12 2020-07-08 Verinata Health, Inc. Cell-free dna fragment
DK3374525T3 (en) 2015-11-11 2021-04-06 Resolution Bioscience Inc HIGH-EFFICIENT CONSTRUCTION OF DNA LIBRARIES
US10095831B2 (en) 2016-02-03 2018-10-09 Verinata Health, Inc. Using cell-free DNA fragment size to determine copy number variations
US11514289B1 (en) * 2016-03-09 2022-11-29 Freenome Holdings, Inc. Generating machine learning models using genetic data
WO2018031739A1 (en) * 2016-08-10 2018-02-15 New York Genome Center, Inc. Ultra-low coverage genome sequencing and uses thereof
MX2019002093A (en) 2016-08-25 2019-06-20 Resolution Bioscience Inc Methods for the detection of genomic copy changes in dna samples.
US12100483B2 (en) 2016-12-22 2024-09-24 Grail, Llc Base coverage normalization and use thereof in detecting copy number variation
TW202348802A (en) * 2017-01-25 2023-12-16 香港中文大學 Diagnostic applications using nucleic acid fragments
US11342047B2 (en) 2017-04-21 2022-05-24 Illumina, Inc. Using cell-free DNA fragment size to detect tumor-associated variant
KR20200085783A (en) 2017-10-27 2020-07-15 주노 다이어그노스틱스, 인크. Devices, systems and methods for ultra low volume liquid biopsy
GB201718620D0 (en) * 2017-11-10 2017-12-27 Premaitha Ltd Method of detecting a fetal chromosomal abnormality
SG11202007899QA (en) * 2018-02-27 2020-09-29 Univ Cornell Ultra-sensitive detection of circulating tumor dna through genome-wide integration
US20190287649A1 (en) * 2018-03-13 2019-09-19 Grail, Inc. Method and system for selecting, managing, and analyzing data of high dimensionality
US20190295684A1 (en) * 2018-03-22 2019-09-26 The Regents Of The University Of Michigan Method and apparatus for analysis of chromatin interaction data
CN112203648A (en) * 2018-03-30 2021-01-08 朱诺诊断学公司 Method, apparatus and system for deep learning based prenatal examination
AU2019248635B2 (en) 2018-04-02 2022-01-27 Illumina, Inc. Compositions and methods for making controls for sequence-based genetic testing
US20190316209A1 (en) * 2018-04-13 2019-10-17 Grail, Inc. Multi-Assay Prediction Model for Cancer Detection
CN112888459B (en) 2018-06-01 2023-05-23 格里尔公司 Convolutional neural network system and data classification method
US11574706B2 (en) * 2018-06-28 2023-02-07 10X Genomics, Inc. Systems and methods for visualization of single-cell resolution characteristics
JP6891150B2 (en) * 2018-08-31 2021-06-18 シスメックス株式会社 Analysis method, information processing device, gene analysis system, program, recording medium
US11488716B2 (en) * 2018-10-09 2022-11-01 Ferrum Health, Inc. Method for configuring multiple machine learning classifiers
US11610150B2 (en) 2018-10-09 2023-03-21 Ferrum Health, Inc. Method for computing performance in multiple machine learning classifiers
US11581062B2 (en) 2018-12-10 2023-02-14 Grail, Llc Systems and methods for classifying patients with respect to multiple cancer classes
CA3119980A1 (en) * 2018-12-20 2020-06-25 Guardant Health, Inc. Methods, compositions, and systems for improving recovery of nucleic acid molecules
JP7332695B2 (en) * 2018-12-21 2023-08-23 エフ. ホフマン-ラ ロシュ アーゲー Identification of global sequence features in whole-genome sequence data from circulating nucleic acids
KR102287096B1 (en) * 2019-01-04 2021-08-09 테라젠지놈케어 주식회사 Method for determining fetal fraction in maternal sample
US20210366569A1 (en) * 2019-06-03 2021-11-25 Illumina, Inc. Limit of detection based quality control metric
CN110373477B (en) * 2019-07-23 2021-05-07 华中农业大学 Molecular marker cloned from CNV fragment and related to porcine ear shape character
CN110570902B (en) * 2019-08-27 2023-05-23 深圳百诺精准医疗科技有限公司 Copy number variation analysis method, system and computer readable storage medium
US20210102262A1 (en) * 2019-09-23 2021-04-08 Grail, Inc. Systems and methods for diagnosing a disease condition using on-target and off-target sequencing data
CN115298324A (en) * 2019-12-18 2022-11-04 香港中文大学 Free DNA fragmentation and nucleases
CN111028890B (en) * 2019-12-31 2020-09-11 东莞博奥木华基因科技有限公司 CNV detection method based on correction between run
CN111210873B (en) * 2020-01-14 2023-03-28 西安交通大学 Exon sequencing data-based copy number variation detection method and system, terminal and storage medium
BR112022015073A2 (en) * 2020-02-05 2022-11-16 Univ Hong Kong Chinese METHOD OF ANALYSIS OF A BIOLOGICAL SAMPLE, COMPUTER PROGRAM PRODUCT, STORAGE MEDIA, AND COMPUTER SYSTEM
CN111477275B (en) * 2020-04-02 2020-12-25 上海之江生物科技股份有限公司 Method and device for identifying multi-copy area in microorganism target fragment and application
CN111411144B (en) * 2020-04-21 2023-12-22 深圳华大因源医药科技有限公司 Plasma free DNA marker for diagnosing blood flow infection pathogen
WO2021219114A1 (en) * 2020-04-30 2021-11-04 深圳市真迈生物科技有限公司 Sequencing method, analysis method therefor and analysis system thereof, computer-readable storage medium, and electronic device
KR20220074088A (en) * 2020-11-27 2022-06-03 주식회사 지씨지놈 Method for diagnosing and predicting cancer type based on artificial intelligence
EP4256565A1 (en) * 2020-12-02 2023-10-11 Illumina Software, Inc. System and method for detection of genetic alterations
CN112766428B (en) * 2021-04-08 2021-07-02 臻和(北京)生物科技有限公司 Tumor molecule typing method and device, terminal device and readable storage medium
CN113270138B (en) * 2021-04-13 2023-09-22 杭州博圣医学检验实验室有限公司 Analysis method for enriching fetal free DNA (deoxyribonucleic acid) for copy number variation based on bioinformatics
CN113889187B (en) * 2021-09-24 2022-12-06 上海仁东医学检验所有限公司 Single-sample allele copy number variation detection method, probe set and kit
JP2024538724A (en) * 2021-10-08 2024-10-23 ファウンデーション・メディシン・インコーポレイテッド Method and system for automated calling of copy number alterations
KR20230114952A (en) * 2022-01-26 2023-08-02 권창혁 Cancer diagnosis apparatus and cancer diagnosis method
US20230326549A1 (en) * 2022-03-31 2023-10-12 Illumina, Inc. Copy number variant calling for lpa kiv-2 repeat
CN114464269B (en) * 2022-04-07 2022-07-08 国家超级计算天津中心 Virtual medicine generation method and device and computer equipment
WO2024044749A1 (en) * 2022-08-26 2024-02-29 Fred Hutchinson Cancer Center Cell-free dna sequence data analysis techniques for estimating fetal fraction and predicting preeclampsia
WO2024173756A1 (en) 2023-02-17 2024-08-22 Illumina, Inc. Cell-free dna signals as biomarkers of preeclampsia
CN116597893B (en) * 2023-06-14 2023-12-15 北京金匙医学检验实验室有限公司 Method for predicting drug resistance gene-pathogenic microorganism attribution
CN117116344B (en) * 2023-10-25 2024-07-19 北京大学第三医院(北京大学第三临床医学院) Detection system and method for single-cell level PMP22 repeated variation

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100216153A1 (en) 2004-02-27 2010-08-26 Helicos Biosciences Corporation Methods for detecting fetal nucleic acids and diagnosing fetal abnormalities
CA2615323A1 (en) 2005-06-06 2007-12-21 454 Life Sciences Corporation Paired end sequencing
CA2668818C (en) 2006-10-10 2018-06-26 Xenomics, Inc. Compositions, methods and kits for isolating nucleic acids from body fluids using anion exchange media
US8262900B2 (en) 2006-12-14 2012-09-11 Life Technologies Corporation Methods and apparatus for measuring analytes using large scale FET arrays
KR101829565B1 (en) 2007-07-23 2018-03-29 더 차이니즈 유니버시티 오브 홍콩 Determining a nucleic acid sequence imbalance
US20100331195A1 (en) 2007-10-04 2010-12-30 William Andregg Sequencing Nucleic Acid Polymers with Electron Microscopy
WO2009051842A2 (en) 2007-10-18 2009-04-23 The Johns Hopkins University Detection of cancer by measuring genomic copy number and strand length in cell-free dna
US20100261183A1 (en) 2007-11-01 2010-10-14 Adam Marcus Shlien Method of determining risk for cancer
EP3378951B1 (en) 2008-09-20 2020-05-13 The Board of Trustees of the Leland Stanford Junior University Noninvasive diagnosis of aneuploidy by sequencing
BR112012010708A2 (en) 2009-11-06 2016-03-29 Univ Hong Kong Chinese method for performing prenatal diagnosis, and, computer program product
US9323888B2 (en) * 2010-01-19 2016-04-26 Verinata Health, Inc. Detecting and classifying copy number variation
US9260745B2 (en) 2010-01-19 2016-02-16 Verinata Health, Inc. Detecting and classifying copy number variation
EP2526415B1 (en) * 2010-01-19 2017-05-03 Verinata Health, Inc Partition defined detection methods
EP2591433A4 (en) 2010-07-06 2017-05-17 Life Technologies Corporation Systems and methods to detect copy number variation
US9029103B2 (en) 2010-08-27 2015-05-12 Illumina Cambridge Limited Methods for sequencing polynucleotides
US8725422B2 (en) * 2010-10-13 2014-05-13 Complete Genomics, Inc. Methods for estimating genome-wide copy number variations
US8741811B2 (en) 2010-11-30 2014-06-03 The Chinese University Of Hong Kong Detection of genetic or molecular aberrations associated with cancer
US9411937B2 (en) 2011-04-15 2016-08-09 Verinata Health, Inc. Detecting and classifying copy number variation
ES2605372T3 (en) 2011-05-31 2017-03-14 Berry Genomics Co., Ltd. A device to detect the number of copies of fetal chromosomes or tumor cell chromosomes
ES2512448T3 (en) 2011-06-29 2014-10-24 Bgi Diagnosis Co., Ltd. Non-invasive detection of fetal genetic abnormalities
JP6161607B2 (en) 2011-07-26 2017-07-12 ベリナタ ヘルス インコーポレイテッド How to determine the presence or absence of different aneuploidies in a sample
US9367663B2 (en) 2011-10-06 2016-06-14 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
EP2764459B1 (en) 2011-10-06 2021-06-30 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
PL2772549T3 (en) 2011-12-31 2019-12-31 Bgi Genomics Co., Ltd. Method for detecting genetic variation
PL2805280T3 (en) 2012-01-20 2022-11-21 Sequenom, Inc. Diagnostic processes that factor experimental conditions
US9892230B2 (en) 2012-03-08 2018-02-13 The Chinese University Of Hong Kong Size-based analysis of fetal or tumor DNA fraction in plasma
CA2866324C (en) 2012-03-13 2019-01-15 The Chinese University Of Hong Kong Methods for analyzing massively parallel sequencing data for noninvasive prenatal diagnosis
CN108485940B (en) * 2012-04-12 2022-01-28 维里纳塔健康公司 Detection and classification of copy number variation
US10504613B2 (en) 2012-12-20 2019-12-10 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US9920361B2 (en) 2012-05-21 2018-03-20 Sequenom, Inc. Methods and compositions for analyzing nucleic acid
US11261494B2 (en) 2012-06-21 2022-03-01 The Chinese University Of Hong Kong Method of measuring a fractional concentration of tumor DNA
CA2878246C (en) 2012-07-20 2022-01-11 Verinata Health, Inc. Detecting and classifying copy number variation in a cancer genome
US20140066317A1 (en) * 2012-09-04 2014-03-06 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
KR102028375B1 (en) 2012-09-04 2019-10-04 가던트 헬쓰, 인크. Systems and methods to detect rare mutations and copy number variation
CA2922005A1 (en) 2012-09-27 2014-04-03 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
GB2528205B (en) 2013-03-15 2020-06-03 Guardant Health Inc Systems and methods to detect rare mutations and copy number variation
US20140371078A1 (en) * 2013-06-17 2014-12-18 Verinata Health, Inc. Method for determining copy number variations in sex chromosomes
KR20220133309A (en) 2013-06-21 2022-10-04 시쿼넘, 인코포레이티드 Methods and processes for non-invasive assessment of genetic variations
KR102373647B1 (en) 2013-10-21 2022-03-11 베리나타 헬스, 인코포레이티드 Method for improving the sensitivity of detection in determining copy number variations
US10415083B2 (en) 2013-10-28 2019-09-17 The Translational Genomics Research Institute Long insert-based whole genome sequencing
BR112016027848A2 (en) 2014-05-30 2017-08-22 Verinata Health Inc METHOD FOR EVALUATION OF THE NUMBER OF COPIES OF A SEQUENCE OF INTEREST, NON-TRANSITORY MACHINE- READABLE MEDIUM, AND, SYSTEM FOR EVALUATION OF THE NUMBER OF COPIES OF A SEQUENCE OF INTEREST
EP3502273B1 (en) 2014-12-12 2020-07-08 Verinata Health, Inc. Cell-free dna fragment
US10364467B2 (en) 2015-01-13 2019-07-30 The Chinese University Of Hong Kong Using size and number aberrations in plasma DNA for detecting cancer
US10368909B2 (en) 2015-02-26 2019-08-06 Titan Medical Inc. Apparatus for providing access for a surgical procedure
US10095831B2 (en) * 2016-02-03 2018-10-09 Verinata Health, Inc. Using cell-free DNA fragment size to determine copy number variations
US11342047B2 (en) 2017-04-21 2022-05-24 Illumina, Inc. Using cell-free DNA fragment size to detect tumor-associated variant

Also Published As

Publication number Publication date
CA3013572C (en) 2023-01-17
CA3013572A1 (en) 2017-08-10
IL272710A (en) 2020-04-30
MA44822A (en) 2017-08-09
IL260938B (en) 2020-03-31
EP3517626B1 (en) 2024-02-07
EA201891580A1 (en) 2019-01-31
KR102049191B1 (en) 2019-11-26
CN108884491A (en) 2018-11-23
CY1121741T1 (en) 2020-07-31
US20230044849A1 (en) 2023-02-09
ZA201805753B (en) 2019-04-24
IL272710B (en) 2021-05-31
KR20180123020A (en) 2018-11-14
AU2019203491A1 (en) 2019-06-06
DK3202915T3 (en) 2019-06-24
EP3202915B1 (en) 2019-03-20
SA518392138B1 (en) 2024-01-29
AR107192A1 (en) 2018-03-28
EA202090277A3 (en) 2020-10-30
CN113096726A (en) 2021-07-09
AU2019203491B2 (en) 2021-05-27
WO2017136059A1 (en) 2017-08-10
US20170220735A1 (en) 2017-08-03
US11430541B2 (en) 2022-08-30
KR102184868B1 (en) 2020-12-02
BR112018015913B1 (en) 2019-12-03
TW201805429A (en) 2018-02-16
EP3517626A1 (en) 2019-07-31
TW201930598A (en) 2019-08-01
NZ745637A (en) 2019-05-31
EA202090277A2 (en) 2020-07-31
EA035148B1 (en) 2020-05-06
CN108884491B (en) 2021-04-27
NZ752319A (en) 2021-01-29
TWI661049B (en) 2019-06-01
AU2016391100A1 (en) 2018-09-27
AU2016391100B2 (en) 2019-03-07
TWI708848B (en) 2020-11-01
CN113096726B (en) 2024-04-26
UA126898C2 (en) 2023-02-22
EP3202915A1 (en) 2017-08-09
US10095831B2 (en) 2018-10-09
BR112018015913A2 (en) 2019-01-22
US20190065676A1 (en) 2019-02-28
MA52131A (en) 2019-07-31
EP3517626C0 (en) 2024-02-07
KR20190132558A (en) 2019-11-27

Similar Documents

Publication Publication Date Title
SG11201806595UA (en) Using cell-free dna fragment size to determine copy number variations
SG11201810003UA (en) Using programmable dna binding proteins to enhance targeted genome modification
SG11201810331YA (en) Single chain variable fragment cd3 binding proteins
SG11201803666WA (en) Single image detection
SG11201903836QA (en) Image-based vehicle damage determining method, apparatus, and electronic device
SG11201805906WA (en) Diagnostic and prognostic methods for cardiovascular diseases and events
SG11201907679TA (en) Business verification method and apparatus
SG11201804190YA (en) Method and system for blockchain variant using digital signatures
SG11201807334SA (en) Methods, compositions, and devices for information storage
SG11201909420QA (en) Picture-based vehicle loss assessment method and apparatus, and electronic device
SG11201900979VA (en) Network-based automated prediction modeling
SG11201806650VA (en) Systems and methods for providing a personal distributed ledger
SG11201811343SA (en) System and methods for detecting online fraud
SG11201903141QA (en) Business processing method and apparatus
SG11201901296TA (en) Compositions and methods for detecting rare sequence variants
SG11201803667RA (en) Systems and methods for region-adaptive defect detection
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201902667UA (en) Methods and systems for chromatography data analysis
SG11201407888RA (en) Method of sequence determination using sequence tags
SG11201810924WA (en) System and method for secondary analysis of nucleotide sequencing data
SG11201806284TA (en) Low pressure separator having an internal divider and uses therefor
SG11201906413XA (en) Exposure apparatus
SG11201811333RA (en) Solid inspection apparatus and method of use
SG11201810907UA (en) Target reporter constructs and uses thereof
SG11201811108YA (en) Method and system for providing sales information and insights through a conversational interface